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Reproducibility: reliability and agreement 
parameters of the Revised Short McGill Pain 
Questionnaire Version-2 for use in patients 
with musculoskeletal shoulder pain
Samuel U. Jumbo1* , Joy C. MacDermid1,2,3, Tara L. Packham2, George S. Athwal3 and Kenneth J. Faber3
Abstract 
Background: The Revised Short McGill Pain Questionnaire Version-2 (SF-MPQ-2) is a multidimensional outcome 
measure designed to capture, evaluate and discriminate pain from neuropathic and non-neuropathic sources. A 
recent systematic review found insufficient psychometric data with respect to musculoskeletal (MSK) health condi-
tions. This study aimed to describe the reproducibility (test–retest reliability and agreement) and internal consistency 
of the SF-MPQ-2 for use among patients with musculoskeletal shoulder pain.
Methods: Eligible patients with shoulder pain from MSK sources completed the SF-MPQ-2: at baseline (n = 195), and 
a subset did so again after 3–7 days (n = 48), if their response to the Global Rating of Change (GROC) scale remained 
unchanged. Cronbach alpha (α) and intraclass correlation coefficient  (ICC2,1), and their related 95% CI were calculated. 
Standard error of measurement (SEM), group and individual minimal detectable change (MDC90), and Bland–Altman 
(BA) plots were used to assess agreement.
Results: Cronbach α ranged from 0.83 to 0.95 suggesting very satisfactory internal consistency across the SF-MPQ-2 
domains. Excellent  ICC2,1 scores were found in support of the total scale (0.95) and continuous subscale (0.92) scores; 
the remaining subscales displayed good  ICC2,1 scores (0.78–0.88). Bland–Altman analysis revealed no systematic bias 
between the test and retest scores (mean difference = 0.13–0.19). While the best agreement coefficients were seen on 
the total scale (SEM = 0.5;  MDC90individual = 1.2 and  MDC90group = 0.3), they were acceptable for the SF-MPQ-2 subscales 
(SEM: range 0.7–1;  MDC90individual: range 1.7–2.3;  MDC90group: range 0.4–0.5).
Conclusion: Good reproducibility supports the SF-MPQ-2 domains for augmented or independent use in MSK-
related shoulder pain assessment, with the total scale displaying the best reproducibility coefficients. Additional 
research on the validity and responsiveness of the SF-MPQ-2 is still required in this population.
Keywords: Reproducibility, Reliability, Agreement, McGill pain questionnaire, Shoulder pain, Musculoskeletal 
conditions, Patient-reported outcomes, Psychometric properties
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Background
Shoulder disorders are among the three leading causes of 
musculoskeletal (MSK) pain, third only to neck pain and 
low back pain [1, 2]. The prevalence of shoulder disorders 
increases with aging [3, 4]. Shoulder disorders are asso-
ciated with substantial consequences for the socioeco-
nomic wellbeing of the patient and society; studies have 
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linked workers’ absenteeism, job loss, and poor health-
related quality of life (HRQoL) to symptoms associated 
with shoulder disorders [3, 5–8].
Pain assessment in clinical practice and research often 
places emphasis on monitoring pain intensity, even 
though pain is known to be multidimensional and expe-
rienced uniquely by individuals [9]. Patients perceive 
pain across six diverse dimensions: physiologic, sensory, 
affective, cognitive, behavioral and socio-cultural [9, 10]. 
The comprehensive assessment and monitoring of these 
dimensions should improve patient care [11]. A multidi-
mensional pain assessment tool that provides a holistic 
assessment of pain has been recommended by experts 
[12–14] for use in upper extremity conditions, including 
shoulder disorders.
The Revised Short McGill Pain Questionnaire Ver-
sion-2 (SF-MPQ-2) is an example of a general use multi-
dimensional pain tool that comprehensively examines the 
sensory and affective dimensions of pain. Dworkin et al. 
[15] created the SF-MPQ-2 by adding seven new items 
that explicitly examines neuropathic and non-neuro-
pathic pain characteristics to the original 15-item Short 
McGill Pain Questionnaire (SF-MPQ). They also replaced 
the previous 4-point descriptive rating scale with a 
10-item numerical rating scale to enhance its respon-
siveness [15]. Since then, multiple studies have utilized 
the SF-MPQ-2 as a primary outcome for pain assess-
ment in clinical trials; its measurement properties have 
been examined in different populations including cancer 
pain [16], surgical pain [17], visceral pain [18], and neu-
ropathic pain [19]. Among MSK conditions, studies have 
reported measurement evidence for patients with com-
plex regional pain syndrome [20], back pain [21], knee 
osteoarthritis (OA) [22], and mixed MSK populations 
[23, 24]. Although the SF-MPQ-2 is becoming increas-
ingly popular, our recent review [25–27] reported on evi-
dence with design flaws including inadequate description 
of Intraclass correlation coefficient (ICC) models, insuf-
ficient justification of retest interval, and a lack of atten-
tion to absolute reliability parameters.
In the absence of such evidence, the primary purpose 
of this study was to investigate the reproducibility (test–
retest reliability and agreement) and internal consistency 
of the Revised Short McGill Pain Questionnaire Ver-
sion-2 (SF-MPQ-2) among persons with MSK-related 
shoulder disorders.
Methods
This study was based on a cross-sectional study of inter-
nal consistency and test–retest reliability. The SF-MPQ-2 
questionnaire was administered to examine reproduc-
ibility (test–retest reliability and agreement) and inter-
nal consistency at two time points: at baseline and after 
3–7  days (when patients would, for the most part, be 
stable) [28, 29]. The participants were recruited from the 
Roth-McFarlane Hand and Upper Limb Centre (HULC), 
London, Ontario, Canada during a period of 6-months 
(June to November 2018). Ethics approval for a clinical 
database of routine outcome measures from which this 
data were extracted was approved by the University of 
Western Ontario Research Ethics Board (REB# 4986).
Patients
Adults proficient in English, above 18  years of age, that 
experienced pain from one or more shoulder conditions 
of known MSK source (for example: rotator cuff tear or 
tendinopathy, adhesive capsulitis, glenohumeral anterior 
instability, and superior labral anterior–posterior (SLAP) 
lesions) were included. Potential participants were 
excluded if they had: (1) an unstable cardiorespiratory 
condition; (2) any history of problems relating with the 
central nervous system e.g. hemiplegia; (3) pain result-
ing from neoplastic or infectious or vascular disorders or 
referred from internal organs; (4) any neuropathic pain 
symptoms resulting from thoracic outlet syndrome, car-
pal tunnel syndrome or any peripheral nerve entrapment, 
or (5) did not provide consent.
Procedure
Assessors (SJ and HULC research assistants) identified 
eligible participants by reviewing the outpatient appoint-
ment list of patients scheduled for a clinical visit with 
two shoulder surgeons (KF and GA), a day prior. Poten-
tial participants were then contacted on the day of their 
clinical appointment and screened to ensure all criteria 
were satisfied; they were provided with an explanation of 
the objectives of the study before a questionnaire booklet 
containing the SF-MPQ-2 and Global Rating of Pain Scale 
(GROC) was administered. Each participant was verbally 
instructed to carefully read and circle the response that 
described their pain experience. In cases where partici-
pants had difficulty with selecting an answer, they were 
told to choose the answer that comes closest to describ-
ing their pain symptoms. If help was needed with under-
standing any words or phrases, or with marking their 
responses, the assessors assisted. The participants were 
instructed to complete all items in the questionnaire. 
Participants were permitted to withdraw from the study 
for any reason at any time. For the second test occasion, 
a subset of the participants (102 in total) that verbally 
confirmed being in unchanged/stable pain in the past 
7-days were conveniently sampled to self-complete the 
SF-MPQ-2 and GROC at home within 3–7 days, if their 
pain remained unchanged (i.e. if they could confirm that 
the threshold of their perceived pain for their shoulder 
disorder had not changed in the past week). The GROC 
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scale was administered, intentionally, on both test occa-
sions solely to serve as an objective means of comparing 
participants test and retest responses thus ensuring that 
only participants in stable/unchanged pain conditions 
were included in our analysis of reproducibility (test–
retest reliability and agreement). Demographic informa-
tion including age, hand dominance, primary cause of 
shoulder pain and sex were recorded.
Outcome measure
The Revised Short McGill Pain Questionnaire Version-2 
(SF-MPQ-2) contains 22-items/pain descriptors and 4 
subscales/domains that examine pain intensity and qual-
ity as follows: (1) continuous pain (throbbing, cramping, 
gnawing, aching, heavy, and tender pain); (2) intermit-
tent pain (shooting, stabbing, sharp pain, splitting pain, 
electric-shock, and piercing pain); (3) neuropathic pain 
(hot-burning, cold-freezing, pain caused by light touch, 
itching, tingling or pins and needles, and numbness 
pain), and (4) affective pain (tiring-exhausting, sickening, 
fearful, and punishing-cruel). All the items are bounded 
on a zero (none) to 10 (worst possible) numerical rating 
scale. The mean of the 22-items yields the SF-MPQ-2 
total score, while the mean of the items that comprise 
each of four-subscales yields the summary score for the 
subscale [15, 21]. Higher subscale or total scores sug-
gest greater pain symptoms/experience, and more than 
2 missing values renders patients’ response to the ques-
tionnaire invalid [21]. The SF-MPQ-2 uses a recall period 
of 7-days, instructing the person to base their rating on 
their symptoms in the past week [15].
Statistical analyses
The SF-MPQ-2 total and subscale scores were considered 
as interval variables. Data quality and screening, includ-
ing the percentage of missing data, outliers, and presence 
of floor/ceiling effects was performed. Respondents with 
two or more missing items were excluded, in line with the 
developers’ instructions [21]. Continuous variables were 
descriptively summarized using means and standard 
deviations while percentages were used to report cate-
gorical variables. The data were then examined for nor-
mality with histograms, and the Shapiro–Wilk test. All 
statistical analyses were completed with Microsoft Excel 
Version 2013 and SPSS statistic for Windows™, Version 
25.0. (Armonk, NY: IBM Corp, Released 2017).
Floor/ceiling effects
Floor/ceiling effects for the SF-MPQ-2 were assessed by 
identifying the number of participants with the absolute 
lowest (0-points = floor) and highest (10-points = ceiling) 
scores on the total and subscales. Floor/ceiling effects 
occurring at the magnitude of 15% were considered sub-
stantial [30].
Hypothesis: We expected substantial floor effects on 
the neuropathic and affective subscales of the SF-MPQ-2 
because they evaluate pain dimensions that are relatively 
uncommon in orthopaedic shoulder disorders.
Cross sectional reliability (internal consistency)
Internal consistency, the degree of item inter-related-
ness/equivalence in a Patient-Reported Outcome Meas-
ure (PROM) [30–32], was assessed with Cronbach alpha 
(α) and associated 95% confidence intervals. An α ≥ 0.7 is 
a commonly accepted standard for internal consistency 
reliability. However, redundancy is suggested at α > 0.95 
[30, 32, 33].
Hypothesis: We expected the SF-MPQ-2 to be inter-
nally consistent with Cronbach α at 0.8 or above for its 
subscale scores, and 0.9 or above for its total scores as 
previously reported in the literature [22, 24].
Relative reliability (test–retest reliability)
The intraclass correlation coefficient  (ICC2,1) was used 
to assess the retest reliability of the SF-MPQ-2 total and 
subscales [34].  ICC2, 1 with 95% confidence intervals (CI) 
were computed using the two-way mixed and absolute 
agreement model, that assumes the patients were ran-
domly selected but the occasions were fixed choices [35]. 
We chose an  ICC2,1 absolute agreement over a consist-
ency model because it captures elements of systematic 
bias and is preferred for computing an absolute reliability 
indicator.  ICC2,1 values for the SF-MPQ-2 total and sub-
scale scores were considered Negative ≤ 0.49, Doubtful 
0.50–0.69, Good 0.70–0.89, and Excellent 0.90–1.00 [36].
Hypothesis: We expected good  ICC2,1 scores for group 
level analysis at ≥ 0.80 for the total scale and ≥ 0.70 for 
the subscale scores as previously reported in the litera-
ture [22, 24].
Agreement properties (standard error of measurement [SEM] 
and minimal detectable change [MDC])
Standard error of measurement (SEM) is defined as 
the standard deviation of errors of measurement asso-
ciated with particular test takers’ scores [37]. Table  1 
explains the five equations used for agreement analy-
sis. To define  SEMagreement for the SF-MPQ-2 total 
and subscales scores, the pooled standard devia-
tion calculated from participants’ mean responses to 
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the SF-MPQ-2 domains on both test and retest using 
Eq.  1 [37, 38] and the respective non-transformed 
 ICC2,1 for the SF-MPQ-2 domain under evalua-
tion was keyed into Eq.  2 [37–39] (Table  1). Further, 
the proportion of the resulting SEM per domain to 
the total score of the scale was calculated to yield 
the SEM percentage or SEM%, as previously used 
[39–41] and interpreted as follows: ≤ 5% = very 
good; > 5–≤ 10% = good; > 10–< 20% = doubtful; and 
values above 20% = negative [39].
The minimal detectable change (MDC) or repeatabil-
ity coefficient describes the minimum amount of change 
that must occur on a score to be confident that true/real 
change (that may or may not be clinically significant) 
has occurred without error after two repeated meas-
ures, within the period of the test–retest [42]. For this 
study, a 90% confidence interval was estimated for the 
Minimal Detectable Change  (MDC90). Like the SEM, it 
is also expressed in the unit of the measure and may be 
computed at an individual level  (MDC90individual) or for a 
group  (MDC90group) [29]. We estimated  MDC90individual for 
the total and subscale scores of the SF-MPQ-2 by enter-
ing each scale’s  SEMagreement into Eq. 3 (Table 1) assuming 
the data was normally distributed and free of systematic 
error. The  MDC90individual confidence interval was then 
computed from the mean differences (d) of each subscale 
using Eq. 4 (Table 1) [29, 40, 43].
To determine the group level minimal detectable 
change  (MDC90group), which is useful for determining 
if changes have occurred in an entire population, Eq. 5 
(Table 1), the formula proposed by de Vet et al. [30, 44] 
was employed. The proportion of the resulting MDC 
coefficient per SF-MPQ-2 domain to the total score 
of the scale was computed to yield the MDC percent 
score (MDC%) and interpreted as follows: ≤ 5% = very 
good; > 5–≤ 10% = good; > 10–< 20% = doubtful; and 
values above 20% = negative [39, 40].
Bland–Altman Plots (BA Plots)
The Bland–Altman (BA) method was used to visu-
ally examine the agreement between the test and retest 
scores [45, 46]. Scatter plots were created to demon-
strate the differences between the total and subscale 
scores obtained at time one and time two of the test–
retest interval against their mean score for the two time 
points [45–48]. We then calculated the mean difference 
between the two measurement intervals (the ‘bias’) and 
the 95% limits of agreement (LoA) using: LoA = mean 
difference (d) ± 1.96 SD of the mean differences. The BA 
plots were used to visually judge the 95% limits of agree-
ment to determine how well the scores from repeated 
measurements agreed: narrower LoAs suggested better 
agreement at the individual level [29, 47, 49]. Agreement 
at the group level was determined by how close the bias 
(mean difference) was to zero. Also, the distribution of 
scatter points on the BA plots were visually scrutinized 
for evidence of variability or heteroscedasticity, where 
the absence of a linear relationship between test–retest 
mean differences and their mean scores, per subscale, 
suggest the absence of systematic bias [44–48, 50]. Linear 
regression models were used to explore the presence of 
systematic bias. For each domain of the SF-MPQ-2, mean 
scores and differences in mean scores were modelled as 
the independent and dependent variables, respectively. 
The potential for systematic bias was appraised by check-
ing if the prediction of the differences in the mean scores 
was statistically significant [47, 51]. Finally, outliers that 
presented beyond the upper and lower boundaries of the 
LoA were noted and explored [29, 52].
Results
Figure  1 below summarizes the flow of participants 
through the different phases of the study. Of the 238 
eligible patients identified from the review of the sur-
geons’ scheduled appointment list, 195 consenting adults 
Table 1 Summary of equations used in agreement analysis
SEMagreement standard error of measurement (agreement), SDtest standard deviation of test scores, SDretest standard deviation of retest scores, SDpooled pooled standard 
deviation, n sample size, CI confidence interval, MDC90individual individual level minimal detectable change at 90% CI, MDC90group group level minimal detectable change 
at 90% CI, d mean difference, ICC2,1 intraclass correlation coefficient
Equation Formula Purpose
1 SDpooled = (SDtest + SDretest)/2 For estimating pooled standard deviation  (SDpooled) from the test and retest scores. 
The  SDpooled is among the indices required for  SEMagreement estimation
2 SEMagreement = Standard  Deviationpooled × 
√
1− ICC 2,1 For estimating  SEMagreement, which is important for the  MDC90individual estimation
3 MDC90individual = 1.64 × √2 × SEMagreement For determining the point estimate of  MDC90individual, which is required for estimat-
ing the confidence interval range and the  MDC90group scores per subscale of the 
SF-MPQ-2
4 95% CI for  MDC90individual = d ± MDC90individual For computing the 90% confidence interval range for the  MDC90individual score 
obtained for each subscale of SF-MPQ-2
5 MDC90group = MDC90individual /√n × 1.64 For estimating the  MDC90 group score for the entire population
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satisfied the inclusion criteria and provided complete 
data that were considered in our analysis of cross-sec-
tional reliability. For the analysis of test–retest reliabil-
ity and agreement, of the 102 participants that agreed 
to participate in the second test occasion, only 48 out of 
55 stable subjects provided a complete response to SF-
MPQ-2 in a mean of 4 days following the index test.
Table  2 summarizes the characteristic and demo-
graphic distribution of the baseline population. The study 





Potential Participants Identified 
from Surgeons’ Appointment 
schedules and EMR Chart
(n = 238) Did not meet predefined inclusion 
criteria:
1. Did not consent to participate (n= 10)
2. Not English speaking (n = 5)
3. Severe cardiovascular disorder (n = 4)
4. Inpatient booked for surgery (n=11)Participant that completed the 
SF-MPQ-2 at baseline (Time 1) 
(n=208)
Participants for 
Reproducibility Analysis  
(n=195)













(SEM, MDC, BA plots)
and relative (ICC2,1)
reliability assessment





(n = 195)  
Fig. 1 Flow chart of progress through the phases of screening, recruitment, test, retest and data analysis
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with a mean age of 62 years, with different shoulder dis-
orders of various MSK pathologies including rotator 
cuff injuries, humeral fracture and glenohumeral joint 
arthroplasty.
Both the graphical and statistical tests of normality 
revealed the dataset was skewed/abnormal. To address 
the assumption of normality for further analysis, a 
square root calculation was used to transform the data. 
A closer look at the reliability coefficients obtained using 
the transformed and untransformed data revealed only a 
small difference in scores (see Table 3 for results). Para-
metric statistics were used in our analysis because the 
sample size was greater than 30 participants (based on 
the central limit theorem). Despite that, we still examined 
for differences in reproducibility coefficients obtained 
using the transformed and non-transformed ICC scores.
Floor and ceiling effects
The presence of floor/ceiling effect may suggest an out-
come measure is not responsive to detecting improve-
ment (ceiling effect) even though a decline in status can 
be captured, and vice versa for floor effects [21]. The 
number of patients who obtained the absolute maximum 
(Ten, 10) and minimal (zero, 0) scores on the SF-MPQ-2 
total and subscales are summarized in Table 3. The great-
est level of floor effect was observed on the affective sub-
scale at both periods of the test–retest. Substantial floor 
effects were also noted on the neuropathic and inter-
mittent subscales. None of the SF-MPQ-2 indices had 
remarkable ceiling effects.
Internal consistency (cross‑sectional reliability)
Table  4 summarizes the results obtained for cross sec-
tional reliability. The SF-MPQ-2 displayed excellent 
internal consistency with robust α coefficients within 
a range that suggest the absence of redundancy: α coef-
ficients for the total subscale peaked at 0.95 as posited, 
while that for the subscales fluctuated between 0.83 and 
0.86 points. Inter-item correlations were satisfactory, 
ranging from 0.23–0.53 across the scales.
Agreement properties (absolute test–retest reliability)
Table 5 summarizes the agreement parameters support-
ing the SF-MPQ-2 domains. The total scale  SEMagreement 
was very low (0.51points) and approximately 5% of the 
total score of the scale, which is ‘very good’ according to 
Table 2 Patient baseline characteristics (N = 195)
N number of patients, SD standard deviation
Variables N/%
Age in years (mean + SD) (62 + 17) 195/100%
Shoulder disorders
Glenohumeral joint arthroplasty 39/20%
Humeral and others fractures (i.e. clavicular, costal, 
scapular)
23/12%












Table 3 Floor and  ceiling effects for  test–retest scores 
of the SF MPQ-2 total and subscale scores (N = 48)
SF-MPQ-2 Revised Short McGill Pain Questionnaire Version-2, % proportion in 
percentages
Variables Test Retest
Floor Ceiling Floor Ceiling
SF-MPQ-2
Continuous
7/48 = 15% 0 /48 = 0% 4/48 = 8% 1/48 = 2%
SF-MPQ-2
Intermittent
11/48 = 23% 0/48 = 0% 15/48 = 31% 0/48 = 0%
SF-MPQ-2
Affective
19/48 = 40% 1/48 = 2% 20/48 = 42% 0/48 = 0%
SF-MPQ-2
Neuropathic
14/48 = 29% 0/48 = 0% 11/48 = 23% 0/48 = 0%
SF-MPQ-2
Total
3/48 = 6% 0/48 = 0% 4/48 = 8% 0/48 = 0%
Table 4 Cross-sectional reliability of  the  SF-MPQ-2 total 
and subscale scores (N = 195)
SF-MPQ-2 Revised Short McGill Pain Questionnaire Version-2, CI confidence 
interval
Variables Internal consistency (N = 195)
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our criteria. Individual subscale  SEMagreement ranged from 
0.73 to 0.99 (approximately ≤ 10% of the total score), 
which is also ‘good’ according to our criteria. At the indi-
vidual level, acceptable scores within 1.19–2.29 points 
were seen in support of minimal detectable change 
(MDC) at a 90% confidence level. Of all the SF-MPQ-2 
domains, the total scale had the lowest MDC score at 
1.20 points (i.e. 12%) while the intermittent subscale 
had the most substantial MDC scores at 2.29 points (i.e. 
23%). For Group  MDC90, estimates were acceptable and 
expectedly lower than those obtained for  MDC90individual; 
the results fluctuated within 0.28 (total) to 0.54 (intermit-
tent) points across the SF-MPQ-2 domains (Table 5).
Relative test–retest reliability
The test–retest reliability of the SF-MPQ-2 domains 
was rated “Good” to “Excellent” (Table  6). Our results 
for  ICC2,1 were based on an analysis conducted with the 
non-transformed data, as they did not differ from that 
obtained with transformed data.  ICC2,1 scores were high-
est on the continuous and total subscales and rated excel-
lent according to our criteria. The neuropathic, affective 
and intermittent subscales displayed good  ICC2,1 coeffi-
cients (Table 6) in support of relative reliability.
Bland–Altman (BA) analysis/plots
The results of our Bland–Altman analysis are presented 
in Table 6. The Bland–Altman plots superimposed with 
the LoA and mean difference (bias) scores for each 
domain of the SF-MPQ-2 are graphically illustrated 
(Fig.  2a–e).All of the SF-MPQ-2 domains displayed 
acceptable LoA at a 95% confidence level with the high-
est distance ranging 5 points (intermittent subscale). The 
total scale score displayed the narrowest LoA (range = 3 
points), with the remaining subscales within satisfactory 
limits. Mean difference scores (bias) were very acceptable 
for all the SF-MPQ-2 domains (0.15–0.19 points).
Table 5 Agreement parameters (absolute reliability) of the SF-MPQ-2 total and subscale scores (N = 48)
SF-MPQ-2 Revised Short McGill Pain Questionnaire Version-2, CI confidence interval, SEM standard error measurement, MDC minimal detectable change
SEM (%) and MDC (%) is expressed as the proportion of the obtained  SEMagreement or  MDC90individual of domain represented on the SF-MPQ-2 to the total score of the 
scale (i.e. 10 points)
Variables SEMagreement SEM (%) MDC90individual (95% CI) MDC (%) MDC90group
SF-MPQ-2
Continuous
0.8 8 1.8 (− 1.6 to 2.0) 18 0.4
SF-MPQ-2
Neuropathic
0.8 8 1.8 (− 1.7 to 1.9) 18 0.4
SF-MPQ-2
Intermittent
1.0 10 2.3 (− 2.1 to 2.4) 23 0.5
SF-MPQ-2
Affective
0.7 7 1.7 (− 1.5 to 1.8) 17 0.4
SF-MPQ-2
Total
0.5 5 1.2 (− 1.0 to 1.4) 12 0.3
Table 6 Relative reliability of the SF-MPQ-2 total and subscale Scores (N = 48)
SF-MPQ-2 Revised Short-form McGill Pain Questionnaire Version-2, d mean difference (test–retest), SD standard deviation, CI confidence interval, LoA limits of 
agreement, ICC intraclass correlation coefficient






d (SD) 95% CI of d 95% LoA Single measure  ICC2,1 (95% CI)
Transformed data Non‑transformed data
SF-MPQ-2
Continuous
2.8 (2.6) 2.7 (2.6) 0.19 (1.12) − 0.14 to 0.51 − 2.01, 2.38 a0.90 (0.83–0.94) a0.91 (0.84–0.95)
SF-MPQ-2
Intermittent
2.1 (2.3) 2.0 (2.4) 0.15 (1.39) − 0.24 to 0.54 − 2.58, 2.88 a0.82 (0.71–0.90) a0.82 (0.71–0.90)
SF-MPQ-2
Neuropathic
1.5 (1.6) 1.3 (1.7) 0.13 (1.10) − 0.19 to 0.45 − 2.02, 2.28 a0.78 (0.64–0.87) a0.78 (0.64–0.87)
SF-MPQ-2 Affective 1.5 (1.9) 1.3 (2.0) 0.15 (1.01) − 0.14 to 0.45 − 1.83, 2.14 a0.85 (0.75–0.92) a0.87 (0.78–0.92)
SF-MPQ-2 Total 2.0 (1.9) 1.9 (2.0) 0.15 (0.73) − 0.06 to 0.37 − 1.29, 1.59 a0.92 (0.86–0.96) a0.93 (0.87–0.96)
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Visual inspection of scatter points on the BA plots for 
each domain of the SF-MPQ-2 revealed that the mag-
nitude of the mean differences against the mean scores 
were uniformly distributed from the zero point and 
most scatter points were within the 95% LoA with the 
exception of a few outliers. This supports the absence of 
systematic bias and suggest a good level of agreement 
among test–retest scores. Furthermore, for each of the 
SF-MPQ-2 domains, there was no evidence of the mean 
difference scores predicting the mean average after our 
regression model analysis. These findings suggest that 
systematic bias is unlikely and confirms good level of 






















































































































































































Mean SF-MPQ-2 Affective (Test-retest)
Fig. 2 a–e The Bland–Altman Limits of Agreement (LoA) plots between the test and retest scores of the SF-MPQ-2 Total (a), Neuropathic (b), 
Intermittent (c), Continuous (d) and Affective (e) subscale scores (n = 48). The difference between test–retest scores is plotted against the mean 
of test and retest scores for the respective SF-MPQ-2 total and subscales depicted. On each plot, the central blue line represents the mean of intra 
individual differences (d); the upper and lower horizontal broken lines represent the 95% LoA. The 95% LoA shows that 95% of the intra individual 
differences are within ± 1.96 SD of the mean difference (d). The outlier noted in each BA plot is numbered, according to participant #RS I.D., and 
presented in accordance with the SF-MPQ-2 subscale or total scores in which they were noted
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The few outliers noted were explored. First, we deter-
mined if they were erroneous responses in entry by 
rechecking hard copies but, indeed, they were ‘interest-
ing’ outliers [53] and labelled according to their #RS on 
each BA plot. The greatest number of interesting outli-
ers presented on the intermittent (n = 6, 12%) and neu-
ropathic (n = 4, 10%) subscales. The least number of 
outliers were seen on the affective subscale (n = 2, 4%). In 
general, however, the presence of these outliers did not 
indicate the presence or absence of bias [53].
Discussion
This study provides reproducibility evidence that sup-
ports the use of the SF-MPQ-2 in multidimensional 
pain assessment of people with MSK shoulder pain. The 
SF-MPQ-2 displayed good to excellent coefficients in 
support of its relative reliability and absolute reliability 
properties. The limits of agreement for the subscales and 
total scores were very satisfactory.
The substantial floor effect observed on the neu-
ropathic, intermittent and affective subscales can be 
attributed to the robust discriminative properties of the 
SF-MPQ-2 subscales and to the lower prevalence of these 
problems in our study population. Conceptually, the SF-
MPQ-2 was expanded to provide a single tool that can 
classify pain between neuropathic and non-neuropathic 
sources [15, 21]. As outcome measures can be evaluative 
or discriminative, combining both purposes within an 
outcome measure is likely to result in these types of sta-
tistical issues. For instance, participants with pain emerg-
ing from neuropathic sources will be more inclined to 
respond adequately to the neuropathic subscale, thereby 
reducing the likelihood of floor effects. This has been 
observed with the use of the SF-MPQ-2 among com-
plex regional pain syndrome (CPRS) patients [20]. This 
implies that floor effects on the SF-MPQ-2 domains may 
not always represent redundancy, but rather, may suggest 
that an item does not describe the patient’s pain experi-
ence [25].
Cross sectional reliability was established for the SF-
MPQ-2 total and subscale scores with satisfactory coef-
ficients supporting internal consistency that are similar 
to previous estimates among mixed-MSK[23] (total, 0.93; 
subscale, 0.84–0.92), CRPS [20] (total, 0.95; neuropathic 
subscale, 0.83), knee OA [22] (total, 0.88; subscale 0.75–
0.81) and acute back pain [21] (total, 0.93; subscale, 0.77–
0.84) patient populations. Inter-item correlations were 
also adequate. The adequate Cronbach’s alpha obtained 
signifies the absence of redundancy in the domains of SF-
MPQ-2 thus confirming their unidimensionality [32] to 
capture the different pain characteristics they assess.
In the present study,  ICC2,1 coefficients were good to 
excellent for all the SF-MPQ-2 domain scores (total, 
0.93; subscales, 0.78–0.91), suggesting that they can 
adequately discriminate among patients at the individual 
level (total and continuous scale) and at the group level 
(all of the SF-MPQ-2 domains) [29, 54]. These results 
are comparable or better than previous findings report-
ing estimates among knee OA [22] (total scale, 0.90; sub-
scales, 0.73–0.90) and mixed MSK patients [24, 55] (total 
scale, 0.90–0.94; subscales, 0.73–0.90). Although accept-
able, the lower performance of the neuropathic subscale 
(0.78), with an ICC score that overlapped the ‘moder-
ate’ confidence interval threshold (0.64–0.87), suggests 
greater variability on this subscale, which makes it more 
difficult to achieve a high  ICC2,1 score.
Absolute reliability estimates allow clinicians to assess 
true change in a patient in comparison to change that 
might be expected from measurement error [30, 44]. 
Currently, no previous data have examined absolute reli-
ability indices for the SF-MPQ-2 scores in any popula-
tion. This makes direct interpretation and comparison 
difficult; however, our use of the Ostelo et  al. [39] defi-
nition of SEM and MDC by percentages allows compari-
son across the domains of the SF-MPQ-2, and with its 
former version (SF-MPQ). The SEM for the total score 
(≤ 5% of total scale score) was ‘very good’ and compa-
rable to that reported for the former version (SF-MPQ) 
among OA patients (≤ 3.64%) [56], but better than those 
seen among mixed MSK patients assessed with the Nor-
wegian version of the SF-MPQ (≤ 10%) [41]. Although 
not as favorable as estimates noted on the total scale, 
the affective and intermittent/continuous subscales had 
‘good’ SEM coefficients (< 10%), which were comparable 
to findings reported with the sensory subscale of the for-
mer SF-MPQ version among OA patients (< 10%) [56], 
and superior to that reported in a mixed MSK popula-
tion (< 14%) [41]. Basically, SEM estimates for all the 
SF-MPQ-2 subscales were satisfactory and suggest an 
adequate evaluative capacity that can yield scores less 
prone to error when utilized by researchers/clinicians for 
MSK shoulder pain assessment over time.
The MDC scores represent the minimal change in 
scores after repeated administration that clinicians/
researchers can interpret as not due to chance vari-
ation for an individual or group in a population [42]. 
The  MDC90indivdiual scores obtained for the SF-MPQ-2 
domains implies that change at a magnitude equal or 
greater than 1.8 (neuropathic), 1.7 (affective), 1.8 (con-
tinuous), 2.3 (intermittent), 1.2 (total) points represents 
genuine improvement beyond chance with 90% con-
fidence. The MDC scores for the total scale (≤ 12% of 
the total score of the scale) were comparable to previ-
ous studies with the former version (SF-MPQ) among 
OA patients (≤ 11.5%) and better than the results seen 
among mixed MSK patients (≤ 26.4% of total score). For 
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the  MDC90group scores, the results obtained for the SF-
MPQ-2 domains imply that a change of at least 0.4 (affec-
tive), 0.5 (intermittent), 0.3 (total), 0.4 (neuropathic), 0.4 
(continuous) points must be observed in a group to be 
90% confident that this was change beyond random or 
systematic error. In general, minimal detectable change 
scores are useful when interventions are administered; to 
be sure the intervention is effective, it must demonstrate 
change beyond the MDC score reported for the scale. 
Also,  MDC90group indices can be used for sample size esti-
mation in a randomized controlled trial, as they deter-
mine the number of participants that will be needed to 
detect a change in the measure beyond error for a group, 
if the Minimal Clinically Important Difference (MCID) 
score for the population is unknown.
The Bland–Altman plots revealed satisfactory lim-
its of agreement in support of the SF-MPQ-2 subscales. 
However, the interpretation of how far apart two meas-
urements can be before they are no longer considered 
interchangeable depends on the contextual application 
[47]. The limits of agreement between the test–retest of 
the SF-MPQ-2 domains were reasonably smaller than 
those seen in previous studies of its former version (SF-
MPQ) [41, 56], suggesting there is less variation between 
the test and the retest of the SF-MPQ-2 [50]. Further-
more, no bias was found in the measurements between 
the test–retest, as the inter-occasion mean difference was 
minimal. This suggests that learning or test accommo-
dation are not issues with using the SF-MPQ-2; moreo-
ver, our compliance to recommended time intervals 
(3–7 days) [28, 29, 57] may have favored the agreement 
outcomes. The intermittent subscale had the greatest 
number of outliers of all the Bland–Altman plots (12%) 
and may be due to the volatile nature of the pain descrip-
tors comprising the scale.
The SF-MPQ-2 total scores displayed the best repro-
ducibility parameters in support of its relative, absolute 
and level of agreement parameters. This could be from 
the number of items contained in the scale. For instance, 
better ICC scores can be expected when variability is low. 
Variability decreases when a greater number of descrip-
tors comprise a scale, in comparison to those with fewer 
descriptors [29]. As all 22 items of the SF-MPQ-2 con-
tribute to the summary total scale scores, it is possible 
this favors reproducibility.
Study limitations
While the present study findings provide preliminary evi-
dence supporting the reproducibility of the SF-MPQ-2 
for use in patients with shoulder disorders, it has several 
limitations. First, the study sample size (48 participants) 
was just under 50 participants which has been suggested 
as a benchmark by the COSMIN [58, 59]. However, in 
conflict with the COSMIN recommendation, our sam-
ple size calculation suggested at least 46 patients were 
required (see Appendix  1), which indicates our study 
was adequately powered. Second, the patient popula-
tion were from a single tertiary referral practice and our 
findings may not be generalizable to a different context. 
Third, since participants completed the retest (Time 2) 
at home, we were unable to clarify instructions. How-
ever, independent completion is a requirement for rou-
tine administration. Further, the high level of agreement 
between scores of the tests and the absence of systematic 
bias suggest this was not a problem. Fourth, sample mean 
age was 62 (± 17) years, which may not adequately reflect 
the reliability of younger populations although shoulder 
pathology prevalence increases with age. Finally, we did 
not determine minimal clinically important difference.
Conclusion
We conclude that the SF-MPQ-2 is satisfactorily inter-
nally consistent and provides good to excellent reproduc-
ibility coefficients (test–retest reliability and agreement) 
for multidimensional pain assessment among patients 
with musculoskeletal shoulder pain conditions. The total 
scale displays the best reproducibility coefficients. Addi-
tional research on the validity and responsiveness of the 
SF-MPQ-2 is still required in this population.
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Appendix 1: Formula used for sample size 
calculation
where:
• k = number of occasions = 2
• Zα represents the Z-value associated with the α value 
of interest. Therefore, Z-value (1-tailed) for 0.05 is 
equivalent to 1.645
• Zβ represents the Z-value associated with a Type 
II error. At power 80%, β equals 0.20, and Z-value 
(1-tailed) equals 0.842.
• δ = R value of Z transformed expected hypothesis 
minus R value of Z transformed null hypothesis, i.e. 
δ = Z Rexpected – Z Rnull
 Where
 Z Rexpected = reliability value expected from analysis
 Rexpected = 0.9
 Z Rnull = lower confidence limit for the desired confi-
dence interval width




• ZRexpected = 0.5 natural log 1+(2−1)0.91−0.9  = 1.47




• Rlowerlimit = 0.09—0.10 = 0.80 (at 0.10 Confidence Inter-
val width)
• Z Rnull = 0.5 natural log 1+(2−1)0.81−0.8  = 1.09
• δ = 1.47 – 1.09 = 0.38






• n = 46 patients
A sample size of 46 participants will be required for the 
reliability analysis.
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